Understanding the Diagnosis
Complex PTSD Is Not Just “More” PTSD
Complex PTSD (C-PTSD) was formally recognized as its own diagnosis in the World Health Organization's ICD-11 (code 6B41). It develops from trauma that is prolonged or repeated and from which escape is difficult or impossible: childhood abuse and neglect, domestic violence, captivity, trafficking, and sustained institutional or interpersonal harm. It is the trauma of years, not of a single afternoon.
A C-PTSD diagnosis requires all three core PTSD clusters — re-experiencing, avoidance, and a persistent sense of current threat — plus a second tier the ICD-11 names disturbances in self-organization (DSO): pervasive difficulty regulating emotion, a durable sense of worthlessness and shame, and profound difficulty feeling close to others or sustaining relationships. These self-organization wounds, not the flashbacks, are what most define daily life with C-PTSD.
This is why so many complex-trauma survivors describe standard PTSD treatment as a poor fit. Prolonged exposure, cognitive processing therapy, and EMDR were developed and validated largely around a single index event to process. C-PTSD has no single event to point to — the injury is woven through identity, emotion, and attachment itself.
The live dashboard below draws directly from MindScape Retreat's clinical database for the PTSD/C-PTSD/TBI Protocol — the combined trauma program in which complex-PTSD patients are treated. We present the data at the program level, honestly, rather than constructing a separate “C-PTSD-only” statistic after the fact: complex-presentation survivors (developmental, relational, and prolonged-captivity trauma) make up a substantial share of this cohort, and the numbers you see are the real, aggregated outcomes for the program that treats them.
The primary outcome instrument is the PCL-5 (PTSD Checklist for DSM-5), scored 0–80 across the four symptom clusters, with a clinical diagnostic threshold of 33. Because C-PTSD adds the self-organization domains — emotion regulation, self-worth, and relational capacity — those dimensions are tracked clinically and through structured integration follow-up rather than a single published scale, and are discussed qualitatively throughout this study.
For complex-trauma survivors, the composite PCL-5 reduction tells only part of the story. The change that matters most in C-PTSD is in the disturbances-in-self-organization cluster: whether a person can feel emotion without being flooded by it, whether the reflexive verdict of “I am worthless” loosens its grip, and whether closeness with another person stops registering as danger. The three domain charts below track exactly these dimensions.
Disturbances in Self-Organization (0 to 10 Scale)
The three ICD-11 self-organization domains that distinguish complex PTSD from standard PTSD, measured at baseline and post-treatment. Emotion regulation and self-worth scored inversely — higher is better; relational threat is impairment, lower is better.
Source: MindScape Retreat PTSD/C-PTSD/TBI cohort (n=73), 6-month follow-up. Domain scales are self-report; PCL-5 is the primary validated instrument.
The PCL-5 remains the anchor because it is the validated, VA-standard measure that lets these outcomes be compared to published trauma research. The chart below shows the cohort's composite PCL-5 trajectory from a severe baseline through the six-month follow-up that distinguishes this study from shorter-duration ibogaine outcomes work — the interval over which complex trauma is most prone to relapse toward baseline.
PCL-5 Symptom Severity — Baseline vs. Follow-Up
The PTSD Checklist for DSM-5 measures symptom severity on a 0 to 80 scale. Clinical diagnostic threshold is 33; scores below 33 represent remission. Values are cohort averages for the combined PTSD/C-PTSD/TBI program.
Source: MindScape Retreat PTSD/C-PTSD/TBI cohort (n=73). Reference: Cherian et al., Nature Medicine 2024.
Why Ibogaine, for This Population
Reaching Wounds That Sit Below the Index Event
Complex PTSD is, neurologically, a set of patterns consolidated over years: a threat-detection system tuned during development, an emotion-regulation circuit that never established a stable baseline, and a self-concept built around danger and shame. These are not memories of an event — they are the architecture the nervous system was built into. That is precisely why event-focused treatments struggle here.
Ibogaine appears to open a prolonged window of heightened neuroplasticity in which these deeply consolidated patterns become accessible for reconsolidation rather than mere management. Its combined action on NMDA and serotonergic systems is associated with restored prefrontal regulation of the amygdala's threat signaling, and its quieting of the default mode network loosens the compulsive self-referential narratives — “I am unsafe, I am unworthy” — that sit at the center of the C-PTSD self-organization cluster.
The mechanism is not a cure, and we are careful never to describe it as one. What it offers complex-trauma survivors is a rare opening in which the relational and identity-level work of recovery can move faster than years of week-by-week therapy alone typically allow — provided that opening is met with structured, trauma-informed integration afterward.
Why a Longer Stay & a TA Booster Protocol
Complex Trauma Needs More Than a Single Window
Single-incident PTSD centers on one index memory, and a single ibogaine flood dose opens a neuroplastic window generally sufficient to reconsolidate it. Complex PTSD is different in kind: the trauma was laid down repeatedly across years and is encoded not as one memory but as a web of them, together with the self-organization patterns — emotion regulation, self-worth, and attachment — built into the developing nervous system itself. Reconsolidating that breadth asks more of a single window than one session can give. This is why complex-trauma patients at MindScape typically follow an extended stay beyond our standard trauma program, structured around a Total Alkaloid (TA) booster schedule rather than a single flood dose alone.
The flood dose initiates the acute neuroplastic cascade; the TA boosters sustain it. TA is the full-spectrum iboga root-bark extract — ibogaine alongside ibogamine, tabernanthine, voacangine, coronaridine, and a higher native content of noribogaine, ibogaine's long-acting metabolite. Noribogaine's extended half-life keeps the system in a receptive, noribogaine-rich state for days rather than hours, and lower-dose TA boosters across additional treatment days hold that window open — and re-open it — giving complex trauma the repeated reconsolidation opportunities its layered structure requires. This also matters for the roughly 7% of people who are CYP2D6 poor metabolizers and convert ibogaine to noribogaine inefficiently: TA supplies noribogaine directly rather than relying on conversion.
The durability rationale rests on established neuroscience. Ibogaine and its alkaloids upregulate GDNF and BDNF, the neurotrophic factors that drive structural neuroplasticity, and repeated administration sustains that expression rather than allowing it to spike and fade (He et al., 2005; Marton et al., 2019) — precisely what an extended booster schedule is designed to do. Separately, controlled research shows psychedelics can reopen the brain's critical period for social reward learning (Nardou et al., 2023, Nature), the very learning system that developmental and relational trauma disrupts. For complex PTSD, whose core injury is to attachment and the sense of self in relation to others, a protocol built to hold that plasticity window open across a longer stay has a direct mechanistic rationale.
We are careful about what this does and does not claim. The neuroplasticity, neurotrophic, and critical-period findings above are established science; the specific multi-alkaloid and booster-schedule design is clinical protocol grounded in that science and in our own outcomes, not a substitute for randomized trials of TA itself. What the extended TA approach offers complex-trauma survivors is more genuine processing capacity within a single medically supervised stay — always paired with the structured integration that turns an open window into lasting change.
How Complex-Trauma Patients Are Assessed and Treated
Cohort & Framing
Outcomes are drawn from the combined PTSD/C-PTSD/TBI observational cohort (n=73): combat veterans, first responders, and civilian survivors — including a substantial subgroup with developmental, relational, and prolonged-interpersonal trauma consistent with ICD-11 complex PTSD. Figures reflect the whole program, not a post-hoc C-PTSD-only subgroup.
Screening for Complex Trauma
Intake documents trauma history, chronicity, and onset age, with explicit attention to the ICD-11 self-organization domains (emotion regulation, self-concept, relational capacity) alongside a PCL-5 baseline. Complex presentations receive additional screening for dissociation and attachment disruption, which shape both dosing and integration planning.
Primary Instrument
PCL-5 (PTSD Checklist for DSM-5, 0–80, clinical threshold 33) is the validated primary outcome, enabling comparison with published trauma research. Self-organization domains are tracked clinically and through integration follow-up rather than a single published scale; PHQ-9 and C-SSRS support comorbidity and safety monitoring.
Assessment Schedule
Baseline, 72h post-treatment, Day 7, Day 14 (discharge), Day 30, Day 90, and Day 180 (6-month) follow-up. The extended six-month endpoint is deliberate: complex trauma is more prone than single-incident PTSD to gradual relapse, so durability is the measure that matters.
Integration Emphasis
Because C-PTSD is relational at its core, aftercare weighting is heavier than for single-incident trauma: referrals prioritize somatic, attachment-focused, and parts/IFS-oriented therapists experienced with complex trauma, with paced integration rather than rapid exposure.
Safety Monitoring
Continuous cardiac telemetry during treatment; C-SSRS at every timepoint; 24/7 clinical access during the inpatient phase; dissociation monitoring at baseline and Day 7. Therapeutic reprocessing is explicitly distinguished from re-traumatization by patients and clinical staff.
What We Observed in Complex-Trauma Survivors
98.6% of the combined PTSD/C-PTSD/TBI cohort (n=72/73) achieved PCL-5 scores below the clinical threshold (< 33) at 6-month follow-up. Complex-presentation patients — those with developmental, relational, and prolonged-interpersonal trauma — were well represented among responders, though the cohort is reported as a whole rather than as a separate C-PTSD subgroup.
Mean PCL-5 reduction of 74% (baseline 62 → 6-month 16), sustained across the extended six-month window. For complex trauma, durability at six months is the more meaningful endpoint, because this population is characteristically prone to gradual relapse that shorter studies miss.
The largest qualitative gains reported by complex-trauma patients were in the self-organization domains that define C-PTSD rather than in re-experiencing alone: a loosening of pervasive shame and worthlessness, improved capacity to feel emotion without being flooded, and reduced threat response in close relationships.
Sleep normalization was frequently the first change patients noticed, often within the first days — clinically important because disrupted sleep interferes with the REM-dependent fear-extinction consolidation on which durable trauma recovery depends.
Integration engagement tracked with durability. Complex-trauma survivors who sustained structured, trauma-informed integration through the 90-day window showed the most stable six-month outcomes — consistent with the clinical consensus that C-PTSD recovery is relational and unfolds over months, not in a single session.
No psychiatric adverse events requiring intervention, and no treatment discontinuations for psychiatric safety. Given elevated dissociation risk in complex trauma, dissociation was monitored specifically; therapeutic reprocessing was consistently distinguished from re-traumatization by patients and staff.
Clinical Protocol
A Protocol Built for Complex Trauma
Complex-Trauma Psychiatric Evaluation
Every candidate undergoes a full psychiatric assessment with explicit attention to complex-trauma features: trauma chronicity and onset age, the ICD-11 self-organization domains, dissociation, and attachment disruption, alongside PCL-5 baseline scoring. Candidates with active suicidality, unstabilized psychosis, or severe cardiac risk are not accepted.
Medical Screening & Safety Clearance
Bloodwork, EKG, cardiac clearance, and a medication interaction review are completed before acceptance. Patients on SSRIs, SNRIs, benzodiazepines, or Z-drugs arrive on their prescribed doses; tapering is performed onsite under continuous physician supervision and telemetry. Pre-arrival contraindications are managed in coordination with the prescribing physician before travel.
Individualized Ibogaine Dosing
Our medical director designs a dosing protocol per patient based on body weight, trauma severity, comorbidities, and therapeutic goals. Complex-trauma protocols typically combine Ibogaine HCl for precision with Total Alkaloid extract for the broader emotional-processing and integration depth these presentations require.
Treatment at MindScape Retreat, Cozumel
Patients receive ibogaine in our medically-equipped sanctuary on Cozumel Island under continuous physician and nurse supervision. For complex trauma, the calm, contained therapeutic environment is not incidental — a felt sense of safety is precisely what these nervous systems never developed, and it shapes the depth of processing that becomes possible.
Relational Integration & 90-Day Aftercare
Complex-trauma recovery is relational and unfolds over months. Every patient departs with an integration plan and referrals to trauma-informed therapists experienced with C-PTSD — emphasizing somatic, attachment-focused, and parts/IFS approaches — plus scheduled check-ins at 30, 60, and 90 days and direct access to our medical director through the acute integration window.
Frequently Asked Questions